JP2018524987A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524987A5
JP2018524987A5 JP2018501339A JP2018501339A JP2018524987A5 JP 2018524987 A5 JP2018524987 A5 JP 2018524987A5 JP 2018501339 A JP2018501339 A JP 2018501339A JP 2018501339 A JP2018501339 A JP 2018501339A JP 2018524987 A5 JP2018524987 A5 JP 2018524987A5
Authority
JP
Japan
Prior art keywords
cell
cells
tcm
phenotype
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501339A
Other languages
English (en)
Japanese (ja)
Other versions
JP7057748B2 (ja
JP2018524987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2016/050775 external-priority patent/WO2017009853A1/en
Publication of JP2018524987A publication Critical patent/JP2018524987A/ja
Publication of JP2018524987A5 publication Critical patent/JP2018524987A5/ja
Application granted granted Critical
Publication of JP7057748B2 publication Critical patent/JP7057748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501339A 2015-07-16 2016-07-14 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用 Active JP7057748B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193207P 2015-07-16 2015-07-16
US201562193229P 2015-07-16 2015-07-16
US62/193,207 2015-07-16
US62/193,229 2015-07-16
PCT/IL2016/050775 WO2017009853A1 (en) 2015-07-16 2016-07-14 Genetically modified anti-third party central memory t cells and use of same in immunotherapy

Publications (3)

Publication Number Publication Date
JP2018524987A JP2018524987A (ja) 2018-09-06
JP2018524987A5 true JP2018524987A5 (enExample) 2019-08-29
JP7057748B2 JP7057748B2 (ja) 2022-04-20

Family

ID=56555512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501339A Active JP7057748B2 (ja) 2015-07-16 2016-07-14 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用

Country Status (11)

Country Link
US (4) US11179448B2 (enExample)
EP (2) EP3322425B1 (enExample)
JP (1) JP7057748B2 (enExample)
CN (3) CN114457039B (enExample)
AU (1) AU2016291825B2 (enExample)
CA (1) CA2991690A1 (enExample)
DK (1) DK3322425T3 (enExample)
ES (2) ES2963038T3 (enExample)
IL (1) IL256916B2 (enExample)
PL (2) PL3322425T3 (enExample)
WO (2) WO2017009852A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010049935A1 (en) 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2753351B1 (en) 2011-09-08 2017-06-21 Yeda Research and Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
DK3322425T3 (da) * 2015-07-16 2023-06-12 Yeda Res & Dev Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
SG11201811563RA (en) 2016-06-27 2019-01-30 Yeda Res & Dev Veto cells generated from memory t cells
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
CN107573419A (zh) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
CN107254489B (zh) * 2017-06-19 2021-06-18 河南省华隆生物技术有限公司 一种检测嵌合抗原受体或基因修饰的t细胞受体表达的方法和应用
WO2019152781A1 (en) * 2018-02-02 2019-08-08 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates
US20210213066A1 (en) * 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
CN112969470A (zh) * 2018-09-10 2021-06-15 阿塔拉生物制药股份有限公司 用于扩增抗原特异性car-t细胞、组合物的方法及其相关用途
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
AU2020261411B2 (en) * 2019-04-26 2025-10-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car T cells
CN110358734B (zh) * 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用
CA3149379A1 (en) * 2019-08-06 2021-02-11 Yeda Research And Development Co. Ltd. Anti-viral central memory cd8+ veto cells in haploidentical stem cell transplantation
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド T細胞媒介性自己免疫疾患の治療におけるベト細胞の使用
WO2021090320A1 (en) * 2019-11-05 2021-05-14 Yeda Research And Development Co. Ltd. Use of veto cells for the treatment of sickle cell disease
EP4110352A4 (en) * 2020-02-28 2024-04-24 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
IL300470A (en) * 2020-08-11 2023-04-01 Yeda res & development co ltd Veto type CAR-T cells
US20240001142A1 (en) * 2020-10-07 2024-01-04 Board Of Regents, The University Of Texas System Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP0668013B1 (en) 1994-02-22 2005-04-20 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same
US5955257A (en) 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
DE69941113D1 (de) 1998-03-03 2009-08-27 Univ Southern California Zytokinen und mitogenen um "graft-versus-host disease" zu verhindern
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
AU2101600A (en) 1998-12-24 2000-07-31 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
EP1274833B1 (en) 2000-04-11 2010-03-10 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
HU226847B1 (en) 2000-07-03 2009-12-28 Bristol Myers Squibb Co Use of soluble ctla4 molecules for treating of rheumatoid arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002043651A2 (en) 2000-11-30 2002-06-06 Yeda Research And Development Co. Ltd. Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030215942A1 (en) 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank
CA2486621A1 (en) * 2002-05-22 2003-12-04 The Cleveland Clinic Foundation Induction and maintenance of tolerance to composite tissue allografts
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
MXPA06001225A (es) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
EP1708737A2 (en) 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
AU2005225227A1 (en) 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-CTLA-4 antibodies
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8354277B2 (en) 2004-10-12 2013-01-15 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells derived from extended blastocysts
HUE030210T2 (en) 2004-11-24 2017-04-28 Hutchinson Fred Cancer Res Methods for using IL-21 to identify adoptive immunotherapy and tumor antigens
LT1868635T (lt) 2005-04-06 2017-07-10 Bristol-Myers Squibb Company Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
EP1928479B1 (en) 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
EP2207875A1 (en) 2007-10-24 2010-07-21 Anne Letsch Antigen-specific t-cell preparations from bone marrow
EP2297200A1 (en) 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
US8200915B2 (en) 2008-08-22 2012-06-12 Cadence Design Systems, Inc. Management of very large streaming data sets for efficient writes and reads to and from persistent storage
WO2010049935A1 (en) 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2494038B1 (en) 2009-10-27 2019-06-26 Immunicum AB Method for proliferation of antigen-specific t cells
ES2686424T5 (es) * 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
CA2805478A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
KR101788826B1 (ko) * 2010-09-08 2017-10-20 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항-백혈병/림프종 치료를 위한 항 서드파티 중앙 기억 t 세포의 용도
MX2013002667A (es) 2010-09-08 2013-08-01 Yeda Res & Dev Una combinacion de farmacos inmunosupresores para un injerto estable y a largo plazo.
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
KR20250020688A (ko) * 2011-04-29 2025-02-11 셀렉타 바이오사이언시즈, 인크. 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
EP2753351B1 (en) * 2011-09-08 2017-06-21 Yeda Research and Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9833482B2 (en) * 2011-12-08 2017-12-05 Yeda Research And Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
DK2793914T3 (da) * 2011-12-22 2021-04-26 Yeda Res & Dev Kombinationsterapi til en stabil og langvarig transplantation
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
MX380109B (es) 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
HK1220205A1 (zh) 2013-03-15 2017-04-28 Celgene Corporation 修饰的t淋巴细胞
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN105408473B9 (zh) * 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
CN106062185A (zh) * 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
BR112017008710A8 (pt) 2014-10-27 2023-04-25 Hutchinson Fred Cancer Res Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
BR112017008693A2 (pt) 2014-10-31 2018-02-27 The Trustees Of The University Of Pennsylvania célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
IL316196A (en) 2015-05-28 2024-12-01 Us Health Methods of conditioning patients for t cell therapy
DK3322425T3 (da) 2015-07-16 2023-06-12 Yeda Res & Dev Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
CN108697776A (zh) 2016-01-11 2018-10-23 阿尔莫生物科技股份有限公司 在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法
ES2886627T3 (es) * 2016-05-22 2021-12-20 Yeda Res & Dev Métodos de uso de células pulmonares para trasplante e inducción de tolerancia
SG11201811563RA (en) 2016-06-27 2019-01-30 Yeda Res & Dev Veto cells generated from memory t cells
US10751368B2 (en) * 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy

Similar Documents

Publication Publication Date Title
JP2018524987A5 (enExample)
JP7317793B2 (ja) 改変γδT細胞
Evans et al. A distinct subset of human NK cells expressing HLA‐DR expand in response to IL‐2 and can aid immune responses to BCG
Bézie et al. Advances on CD8+ Treg cells and their potential in transplantation
JP2019527041A5 (enExample)
Choreno Parra et al. Memory of natural killer cells: a new chance against Mycobacterium tuberculosis?
JP2017512484A5 (enExample)
JP2019518460A5 (enExample)
JP2017535292A5 (enExample)
RU2017111298A (ru) Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
Sagoo et al. Regulatory T cells as therapeutic cells
Fan et al. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood
Ma et al. CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro
JP2014087372A5 (enExample)
RU2013147157A (ru) Способ и композиции для клеточной иммунотерапии
JP2021505604A5 (enExample)
Preite et al. Somatic mutations and affinity maturation are impaired by excessive numbers of T follicular helper cells and restored by Treg cells or memory T cells
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
FI4219687T3 (fi) Menetelmiä immuunisolupopulaatioiden eristämiseksi, viljelemiseksi ja geneettiseksi muokkaamiseksi adoptiivista terapiaa varten
JP2016539929A5 (enExample)
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
Slepicka et al. Harnessing mechanisms of immune tolerance to improve outcomes in solid organ transplantation: a review
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
Seok et al. Roles of virtual memory T cells in diseases